Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Amgen Inc. (AMGN)
The Californer/10233506

SAN DIEGO--(BUSINESS WIRE)--The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Amgen Inc. (NASDAQ: AMGN) common stock between July 29, 2020 and April 27, 2022, for violations of the Securities Exchange Act of 1934. Amgen is one of the world's largest independent biopharmaceutical companies.

What Now: Similarly situated shareholders may be eligible to participate in the class action against Amgen. Shareholders who want to act as lead plaintiff for the class must file their papers by May 12, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

More on The Californer

• Mother's Day Wake-Up Call for Maternal Health: New Initiative Demands Better Postpartum Support
• AMERICAN SKIN ASSOCIATION ANNOUNCES RESEARCH ACHIEVEMENT AWARDS
• Your community classifieds [Vivinavi] offers FREE reservation system
• Southbox Entertainment, FinTech Pioneer & Entrepreneur Jon Gosier Join Psychological Thriller The Dutchman as Financing Partner
• SlotCycle Joins Association of Gaming Equipment Manufacturers (AGEM) to Advance Sustainable Gaming Solutions

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case About: Amgen Inc. (AMGN) Failed to Disclose the Impact of the Company's Tax Liability to Investors

According to the complaint, for years, Amgen has been accused of improperly skirting U.S. tax laws and relying on a profit allocation system that ran afoul of the U.S tax code, with the implication of owing billions in back taxes.

By the start of the class period, and after years of Amgen's failed attempts to avoid receiving notices of deficiency, which would ultimately put the Company on the hook for over $10 billion in taxes and penalties, defendants were compelled to make substantial disclosures regarding the Company's outstanding tax liabilities to investors. Rather than disclose these adverse facts, however, defendants failed to take any meaningful accrual or otherwise reveal the staggering amount of back taxes and penalties claimed by the U.S. government. These material omissions caused the price of Amgen stock to trade at artificially inflated prices throughout the class period, ultimately causing investors to suffer hundreds of millions of dollars in losses when Amgen belatedly revealed the truth.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com

More on The Californer

• Red Willow Art Building New Artist Models For the Future Art Market
• Marketing Strategist Angelo Ponzi Publishes The Strategy Blueprint: Creating Value, Driving Revenue, and Building an Enduring Brand
• Propagate Content Acquires Parker Management
• Transgender Pioneer---A LETTER TO PAWTONE: Releasing May 19th
• Two of San Dimas' Finest Claim Platinum Patriot Sponsorships for 2026 Celebration

Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Amgen Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

---

Show All News | Report Violation